Once a stock-market darling of the genomics boom, 10x Genomics has spent three hard years in the wilderness. A raised 2026 outlook and 'extraordinary' Demand for its new Atera platform have reignited the comeback question — but the numbers demand a closer look.

On 6 August 2026, 10x Genomics (NASDAQ:TXG) reported second-quarter results and nudged up its full-year Revenue guidance, crediting what chief executive Serge Saxonov called "the extraordinary customer response" to Atera, its newest spatial-biology platform, launched in April. Headline revenue actually fell year on year, yet the shares ticked higher in after-hours trading. That apparent contradiction sits at the heart of the bull-versus-bear debate: is this the long-awaited inflection for a company whose stock collapsed from pandemic-era highs, or simply one bright product against a still-difficult research-funding backdrop?

The headline poses a fair question. 10x helped define two of the hottest niches in life-sciences research — single-cell and spatial genomics — but growth stalled as academic budgets tightened and Patent wars raged. Deciding whether a genuine comeback is under way means separating the signal (Atera bookings, expanding margins) from the noise (a reported revenue decline flattered, and then depressed, by one-off litigation payments).

What the Company Does

10x Genomics (LSE:0A88), based in Pleasanton, California, builds instruments and consumables that let scientists analyse biology at the level of individual cells and map gene activity within intact tissue. Its Chromium range dominates single-cell analysis; its Visium and Xenium systems address spatial biology, showing not just which genes are active but where. Atera, launched in April 2026, is its newest spatial platform, which management says offers sensitivity "substantially higher" than rival Xenium technology.

The Business model is razor-and-blades: sell an instrument, then earn Recurring Revenue from the consumable reagents used in every experiment. In the second quarter, consumables generated $130.8m of the $151m total, underscoring how the installed base — not one-off machine sales — drives the model. Customers span academic and government research labs, biopharma companies and, increasingly, clinical and translational settings; newly announced partnerships with the Cleveland Clinic and Lausanne University Hospital point toward oncology-biomarker work.

Why the Stock Is in Focus

The catalyst is the raised guidance and the reception for Atera. 10x lifted full-year 2026 revenue guidance to $610m–$630m, from $600m–$625m — modest in absolute terms, but a signal of confidence after years of downgrades. Management said booked orders for Atera already "greatly exceed" the full-year shipment target of roughly 40 units, with Manufacturing capacity, not demand, now the binding constraint. Deliveries are weighted to the fourth quarter, implying a revenue step-up late in the year.

Saxonov described Atera's April debut as "still by far the biggest highlight of the year." For a company that has repeatedly disappointed, evidence that a new product is genuinely supply-constrained rather than demand-constrained is exactly the kind of narrative shift investors have been waiting for.

Latest Financial Picture

Reported second-quarter revenue was $151.0m, down about 13% year on year. The fall is misleading: the prior-year period included substantial one-off patent-litigation settlement income. Excluding non-recurring settlement items, revenue rose roughly 3% to about $149.4m. Within that, spatial consumables grew 16% to $42.3m, services rose 26% to $10.7m and single-cell consumables edged up 3% to $88.5m, while instrument sales slumped 47% to $7.7m as customers deferred big-ticket purchases.

The company swung to a net loss of $17.9m, or $0.14 a share, from Net Income of $34.5m ($0.28) a year earlier — again reflecting the absence of settlement income. Encouragingly, gross Margin expanded to 74% from 72%, helped by lower manufacturing costs and Tariff refunds. The Balance Sheet remains a genuine strength: cash and marketable securities stood at roughly $552m at 30 June 2026, up from about $523m at the end of 2025. R&D spending fell 7% to $56.8m, while SG&A rose 6% to $78.7m. (Figures per the company's Q2 release and earnings call, as reported by GenomeWeb, Investing.com and TradingKey.)

The Bull Case

The strongest bull argument is that the underlying business is quietly growing again once distortions are stripped out: ex-settlement revenue up 3%, spatial consumables up double digits and margins expanding. Atera adds a credible new growth vector — demand outstripping a 40-unit Supply cap suggests pricing power and pent-up appetite that could feed 2027 as capacity scales. A cash and securities cushion of roughly $550m funds R&D and the recent Proteintech Genomics Acquisition without forced dilution. On our reading, if Atera converts bookings into recurring consumable pull-through, the razor-and-blades flywheel could re-accelerate, while the clinical partnerships hint at a larger, less budget-sensitive market beyond academia.

The Bear Case

Against that, the core end-market remains fragile. Management itself called academic funding "tenuous," with grant dollars slow to translate into orders amid staffing shortages and multi-year budget structures — and instrument sales down 47% show researchers are not yet reinvesting in hardware. Single-cell consumables grew just 3%, hinting the legacy engine is maturing. The guidance raise was small and partly rests on Atera deliveries that are back-end loaded and capacity-constrained, leaving little room for slippage. The company is loss-making again, and a genomics-tools sector still contending with United States research-funding uncertainty offers scant margin for error. Much of the bull case rests on a single product.

What Could Move the Stock Next?

The pivotal near-term catalyst is fourth-quarter execution: whether 10x can actually build and ship its roughly 40 Atera units and convert the order book into revenue and repeat consumable use. Any update on 2027 Atera capacity would matter greatly. Investors will also watch trends in US academic and National Institutes of Health research funding, the pace of clinical and biopharma adoption, integration of the acquired Proteintech Genomics, and progress at the Cleveland Clinic and Lausanne partnerships. Third-quarter results, due in the autumn, will be the next scheduled checkpoint, while the ongoing spatial-biology rivalry with competitors will continue to shape pricing.

Outlook

So is the genomics comeback finally here? The honest answer as of 12 August 2026 is that it is beginning, but unproven. 10x has done the hard part of building a product — Atera — that customers appear to want more of than it can make, and its margins and cash position are moving the right way. Yet the reported revenue decline, renewed losses and a still-shaky academic funding environment are real. On our reading, the quarter marks a plausible turning point rather than a confirmed one. The verdict hinges on fourth-quarter Atera shipments and whether recurring consumables follow. The raised guidance justifies cautious optimism — not celebration.